Promotional Features

This content is provided by Thermo Fisher Scientific.

The following content is provided by an advertiser or created on behalf of an advertiser. It is not written by the BioPharma-Reporter.com editorial team, nor does it necessarily reflect the opinions of BioPharma-Reporter.com.

For more information, please contact us here​.

Notes on compliance: USP 60 compliance doesn’t have to be complicated

Last updated on

When United States Pharmacopeia 60 (USP 60) came into effect little more than a year ago, it added a new dimension to testing for objectionable organisms in pharmaceutical products. 

The regulation, which was triggered by a string of Burkholderia cepacia ​complex (Bcc) infections linked to non-sterile aqueous products, means laboratories are having to build new processes from the ground up. 

It is not easy, but compliance does not have to be complicated. Validated microbial limit databases  and simple tweaks to common workflows will ensure your products remain Bcc free and USP 60 compliant.  

What is USP 60? 

December 2019’s USP 60: Microbiological Examination of Non-sterile Products - Tests for Burkholderia cepacia Complex ​followed a 2017 FDA advisory on the risk of Bcc-contamination in non-sterile, water-based products1​. 

Bcc, a 21-species strong group of water-borne opportunistic pathogens that are resistant to many antibiotics and can remain viable under harsh processing conditions, can lead to dangerous, potentially fatal complications in vulnerable groups.  

In 2005, for example, the Centers for Disease Control was notified of several clusters of Bcc-induced pneumonia linked to a contaminated mouthwash.2​ 

USP 60, then, is about protecting public health therefore non-compliance is not an option – releasing Bcc-contaminated products onto the market can result in a facility being shut down. 

How to implement USP 60 

Building new processes is never easy and implementing USP 60 has been no exception. 

While the regulation addresses the finished product, standard operating procedures (SOPs), must cover each step of the manufacturing process. It is the only way laboratories will be able to understand possible points of entry if contamination is detected. 

One way of doing this is using microbial limit testing (MLT) to validate all components, particularly those most susceptible to Bcc growth, and create a baseline dataset. By repeating MLT at every step of the manufacturing pathway, laboratories can develop a solid understanding of how the bacteria react within the process. 

Workflows will also need to be adapted. It is worth noting that the biochemical reactions involved in detecting B. cepacia, B. cenocepacia, ​and B. mutivorans ​relate to all Bcc species, meaning a single test can confirm the absence of all 21. 

Another consideration is the interpretation of positive results. The possible presence of Bcc is  indicated by the growth of greenish-brown colonies with yellow halos, or white colonies with a pink red zone on Thermo Scientific™ Burkholderia cepacia ​Selective Agar (BCSA).3​Laboratories must  remember, however, that at least pinpoint colony growth should occur within 48 hours, with the  color change happening within 48 to 72 hours. Unlike in many similar workflows, then, the process  contains two, rather than one, vital observation steps.  

Complete for compliance ​ 

Building compliance processes from scratch – particularly for a pathogen like Bcc which is present in  so many environments – can be challenging.  

But with the right preparation and planning, pharmaceutical laboratories can create scientifically  robust SOPs that keep non-sterile aqueous products safe, compliant, and on the shelf.  

For more information on the Thermo Scientific™ complete Bcc workflow take a look at  our USP 60 Smart Note 

Related resources from Thermo Fisher Scientific